Variability in the measured response of bone to teriparatide.

Heaney RP, Watson P

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA9 Sept 2010Cited by 17 (Europe PMC)

PMID20827548DOI10.1007/s00198-010-1376-1PepBankPUB-20827548

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis receiving teriparatide, 85.2% showed a significant spine BMD response.
In plain wordsIn women with osteoporosis receiving teriparatide, 85.2% showed a significant spine bone density response.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSignificant spine BMD response
Study
n = 203
Outcome group
Bone and joint · Musculoskeletal
Measurements
Significant spine BMD response
85.2%
participants
Source sentences
Summary
Of the total number of participants, 85.2% exhibited a significant spine BMD response, while only 44.8% had a significant change at the hip.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 203 postmenopausal women with moderately severe osteoporosis, all treated with teriparatide, calcium, and vitamin D.
Summary · context
This is a prospective study of change in bone mineral density and resorption biomarkers over a 12-month treatment period.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2082754801
02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In postmenopausal women with osteoporosis receiving teriparatide, 44.8% showed a significant hip BMD change.
In plain wordsIn women with osteoporosis receiving teriparatide, 44.8% showed a significant hip bone density change.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedSignificant hip BMD response
Study
n = 203
Outcome group
Bone and joint · Musculoskeletal
Measurements
Significant hip BMD change
44.8%
participants
Source sentences
Summary
Of the total number of participants, 85.2% exhibited a significant spine BMD response, while only 44.8% had a significant change at the hip.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 203 postmenopausal women with moderately severe osteoporosis, all treated with teriparatide, calcium, and vitamin D.
Summary · context
This is a prospective study of change in bone mineral density and resorption biomarkers over a 12-month treatment period.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2082754802
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, mean biomarker response was marginally larger in BMD nonresponders than responders at either site.
In plain wordsIn women receiving teriparatide, biomarker response was slightly larger in bone density nonresponders than responders at either site.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBiomarker response in BMD nonresponders
Study
n: not reported in source
Comparator
BMD responders
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, mean biomarker response was marginally larger for the BMD non-responders at either site than for the responders, indicating biological, if not measurable densitometric, activity of teriparatide in essentially all participants.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 203 postmenopausal women with moderately severe osteoporosis, all treated with teriparatide, calcium, and vitamin D.
Summary · context
This is a prospective study of change in bone mineral density and resorption biomarkers over a 12-month treatment period.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2082754803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00074711

Adding Phosphorus to Osteoporosis Drug Treatment

Creighton Universityn = 241Aug 2004 to Jun 2008

Osteoporosis · Osteopenia

Trial page ClinicalTrials.govUpdated 6 Jul 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.